@article{3000891,
    title = "Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study",
    author = "Taher, A.T. and Karakas, Z. and Cassinerio, E. and Siritanaratkul, N. and Kattamis, A. and Maggio, A. and Rivella, S. and Hollaender, N. and Mahuzier, B. and Gadbaw, B. and Aydinok, Y.",
    journal = "Blood advances",
    year = "2018",
    volume = "131",
    number = "2",
    pages = "263-265",
    publisher = "American Society of Hematology",
    doi = "10.1182/blood-2017-06-790121",
    keywords = "ferritin;  growth differentiation factor 15;  hepcidin;  iron;  ruxolitinib;  transferrin;  transferrin receptor;  pyrazole derivative;  ruxolitinib, anemia;  beta thalassemia;  clinical article;  drug efficacy;  drug withdrawal;  erythrocyte transfusion;  erythrocyte volume;  erythropoiesis;  ferritin blood level;  fever;  hemoglobin E-beta thalassemia;  hormone blood level;  human;  iron blood level;  iron metabolism;  Letter;  multicenter study;  nuclear magnetic resonance imaging;  open study;  patient safety;  phase 2 clinical trial;  priority journal;  protein blood level;  spleen size;  splenomegaly;  staphylococcal bacteremia;  thalassemia;  toxic hepatitis;  transferrin blood level;  upper respiratory tract infection;  virus pneumonia;  beta thalassemia;  erythroid cell;  thalassemia, beta-Thalassemia;  Erythroid Cells;  Erythropoiesis;  Humans;  Pyrazoles;  Thalassemia"
}